Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

MERCK & CO., INC.

(MRK)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/25 08:53:44 am
80.17 USD   -1.00%
07:47aMERCK : Halts Development of COVID-19 Vaccine Candidates
MT
07:18aMERCK : Stops Development of COVID-19 Vaccine Candidates V590 and V591
MT
06:59aMerck Scraps Covid-19 Vaccine Candidates
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck : to Acquire OncoImmune

11/23/2020 | 06:46am EST

Acquisition adds to Merck’s suite of clinical programs in response to SARS-CoV-2/COVID-19

Merck will accelerate development of CD24Fc, a candidate for the treatment of patients with severe and critical COVID-19

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and OncoImmune, a privately-held, clinical-stage biopharmaceutical company, today announced that the companies have entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of OncoImmune for an upfront payment of $425 million in cash. In addition, OncoImmune shareholders will be eligible to receive sales-based payments and payments contingent on the successful achievement of certain regulatory milestones. OncoImmune recently announced positive top-line findings from an interim efficacy analysis of a Phase 3 study evaluating its lead therapeutic candidate CD24Fc for the treatment of patients with severe and critical COVID-19.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201123005593/en/

“Meaningful new therapeutic options are desperately needed for possibly millions of people around the world who will develop severe or critical COVID-19 disease,” said Dr. Roger M. Perlmutter, President Merck Research Laboratories. “Recent clinical investigations support the view that CD24Fc may provide benefit beyond standard of care therapy for COVID-19 patients requiring oxygen support, and hence will represent an important addition to the Merck pipeline of investigational medicines and vaccines designed to address the COVID-19 pandemic.”

Interim analysis of data from 203 participants (75% of the planned enrollment) reported by OncoImmune indicated that patients with severe or critical COVID-19 treated with a single dose of CD24Fc showed a 60% higher probability of improvement in clinical status, as defined by the protocol, compared to placebo. The risk of death or respiratory failure was reduced by more than 50%. Detailed results will be submitted for publication in a peer-reviewed medical journal.

“Outstanding work by the OncoImmune team has provided compelling evidence regarding the use of CD24Fc in patients with severe and critical COVID-19 in our Phase 3 Trial,” said Yang Liu, PhD, Co-founder and Chief Executive Officer of OncoImmune. “We look forward to working with the scientists and manufacturing engineers at Merck as well as regulators as we seek to accelerate the global development of this potentially important therapy.”

Under the agreement, prior to the completion of the acquisition, OncoImmune will spin-out certain rights and assets unrelated to the CD24Fc program to a new entity to be owned by the existing shareholders of OncoImmune. In connection with the closing of the acquisition, Merck will invest $50 million, and become a minority shareholder, in the new entity.

The closing of the acquisition, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected before the end of 2020.

OncoImmune was represented by Goodwin Procter LLP as legal advisor and Guggenheim Securities as financial advisor.

About SAC-COVID Phase 3 Trial

The SAC-COVID Phase 3 clinical trial (NCT04317040) is a randomized, double blind, placebo-controlled trial designed to evaluate the safety and efficacy of CD24Fc in hospitalized patients with COVID-19 requiring oxygen support, including those requiring supplemental oxygen, high flow oxygen, and mechanical ventilation. Participants were randomly assigned into two arms receiving either standard of care plus a single dose of CD24Fc via an intravenous infusion on Day 1 or standard of care plus placebo on Day 1. The multi-center trial was initiated in April 2020 and had enrolled 243 patients when the trial was closed to enrollment in September 2020.

About CD24Fc

OncoImmune’s lead product is CD24Fc, a first-in-class recombinant fusion protein that targets the innate immune system. Prior to the Phase 3 clinical trial for COVID-19 patients, CD24Fc has been studied for safety in healthy volunteers and in Phase 2 clinical trials for the prevention of graft versus host disease (GVHD) following hematopoietic stem cell transplantation in patients with leukemia. A pivotal Phase 3 clinical trial (NCT04095858) for prophylaxis of GVHD has been initiated nationwide.

About Merck’s ongoing Commitment to COVID-19

Merck has been committed to developing an effective response to COVID-19 since the early stage of the pandemic and is exploring multiple paths to advance the understanding of SARS-CoV-2 infection. In collaboration with Ridgeback Biotherapeutics, Merck is evaluating molnupiravir, an investigational orally available anti-viral candidate, in two Phase 2/3 trials, for the treatment of patients with COVID-19 in both the outpatient and inpatient settings.The company is also conducting clinical trials to evaluate two SARS-CoV-2/COVID-19 vaccine candidates: V590, being developed through a collaboration with IAVI, which utilizes a recombinant vesicular stomatitis vector, and V591 which uses a measles virus vector-based platform.

About OncoImmune

OncoImmune is a privately-held, clinical-stage biopharmaceutical company that is actively engaged in the discovery and development of novel biopharmaceuticals for the treatment of cancer and autoimmune disease.

The company’s lead therapeutic candidate CD24Fc has a novel mechanism of action that has potential applications to a number of inflammatory diseases and has shown good safety and tolerability in a Phase 1 clinical trial in healthy volunteers. Clinical activity has been observed in two Phase 2 trials in GVHD and the Phase 3 trial in COVID-19. In addition to CD24Fc, OncoImmune has a rich pipeline of immuno-oncology candidates that will be the focus of the new spinout. OncoImmune has initiated a Phase 1 clinical trial evaluating a novel CTLA-4 antibody candidate that selectively eliminates immune suppressive regulatory T cells in the tumor microenvironment while preserving their physiological function to protect host against autoimmune diseases (NCT04140526). Visit www.oncoimmune.com.

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the recent global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2019 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).


© Business Wire 2020
All news about MERCK & CO., INC.
07:47aMERCK : Halts Development of COVID-19 Vaccine Candidates
MT
07:18aMERCK : Stops Development of COVID-19 Vaccine Candidates V590 and V591
MT
06:59aMerck Scraps Covid-19 Vaccine Candidates
DJ
06:46aMERCK : Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates; Cont..
BU
02:40aEuropean Commission Authorizes Use Of Merck-Pfizer Cancer Drug Bavencio
MT
01/21MERCK : Announces U.S. FDA Approval of VERQUVO
AQ
01/21MERCK : Bayer - U.S. FDA approves vericiguat for patients with symptomatic chron..
AQ
01/20MERCK : Canada and MaRS Team Up to Launch Lung Cancer Innovation Challenge
AQ
01/20MERCK : Gets FDA Approval for Verquvo
DJ
01/20MERCK : Receives US FDA Approval of Heart Failure Treatment Verquvo
MT
More news
Financials (USD)
Sales 2020 48 199 M - -
Net income 2020 12 145 M - -
Net Debt 2020 15 159 M - -
P/E ratio 2020 17,1x
Yield 2020 3,02%
Capitalization 205 B 205 B -
EV / Sales 2020 4,57x
EV / Sales 2021 4,20x
Nbr of Employees 71 000
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 23
Average target price 96,95 $
Last Close Price 80,98 $
Spread / Highest target 32,1%
Spread / Average Target 19,7%
Spread / Lowest Target 4,96%
EPS Revisions
Managers and Directors
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Sandy Tremps Vice President-R&D IT CIO
Thomas Henry Glocer Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-1.00%204 882
JOHNSON & JOHNSON3.92%430 552
ROCHE HOLDING AG3.06%308 615
NOVARTIS AG2.73%220 726
PFIZER INC.-0.71%203 159
ABBVIE INC.3.46%195 720